 Until recently, peritoneal mesothelioma was considered incurable, with a median survival of less than 1 year from diagnosis. Several different approaches had been unsuccessfully attempted in the past, including surgery, systemic chemotherapy, whole abdominal irradiation, and intraperitoneal administration of radioisotopes (<sup>32</sup>P, <sup>198</sup>Au) or antiproliferative drugs (thiotepa, bleomycin) (Antman et al. 1983; Sridhar et al. 1992). No dominant therapeutic guideline currently exists. During t